Spero Therapeutics Consensus Price Target Raised 25% to $5.10
Published . Updated .
The average one-year price target for Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and d
Directly affected
- SPRO Spero Therapeutics
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Spero Therapeutics (NASDAQGS:SPRO) (DB:2HA) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated September 11, 2026. These figures represent aggregate…
Source: Nasdaq Markets
Price since this story was published: Spero Therapeutics (SPRO)
Since the first closing price after “Spero Therapeutics Consensus Price Target Raised 25% to $5.10,” Spero Therapeutics (SPRO) is -3.85%. The S&P 500 fund (SPY) is -1.08% over the same days, a -2.77% difference versus the market.
Who gains and who loses around Spero Therapeutics (SPRO)
Companies mentioned with this story
- SPRO Spero Therapeutics
For “Spero Therapeutics Consensus Price Target Raised 25% to $5.10,” Spero Therapeutics (SPRO) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names Spero Therapeutics Inc in the headline; GA resolved that company to SPRO
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
For “Spero Therapeutics Consensus Price Target Raised 25% to $5.10,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
For “Spero Therapeutics Consensus Price Target Raised 25% to $5.10,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Spero Therapeutics Consensus Price Target Raised 25% to $5.10.” Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Spero Therapeutics Consensus Price Target Raised 25% to $5.10.” Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Spero Therapeutics Consensus Price Target Raised 25% to $5.10.” Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Spero Therapeutics Consensus Price Target Raised 25% to $5.10.” Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Spero Therapeutics (SPRO)
The 2 Oct 2026 story “Spero Therapeutics Consensus Price Target Raised 25% to $5.10” names Spero Therapeutics (SPRO) because of this story.
The link for Spero Therapeutics (SPRO) is this: The reported development directly names Spero Therapeutics Inc in the headline; GA resolved that company to SPRO
Also listed, T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ): GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Spero Therapeutics (SPRO) price range
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. SPRO traded between 1.09 and 1.30 across 15 sessions. The latest close on file is 1.12.
How strong the case is around Spero Therapeutics (SPRO)
46 out of 100
“Spero Therapeutics Consensus Price Target Raised 25% to $5.10” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.